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ABSTRACT Bluetongue virus (BTV) is endemic in many parts of the world, often
causing severe hemorrhagic disease in livestock. To date, at least 27 different sero-
types have been recognized. Vaccination against all serotypes is necessary to protect
susceptible animals and to prevent onward spread of the virus by insect vectors. In
our previous studies, we generated replication-deﬁcient (disabled infectious single-
cycle [DISC]) virus strains for a number of serotypes and reported preliminary data
on their protective efﬁcacy in animals. In this report, to advance the DISC vaccines
to the marketplace, we investigated different parameters of these DISC vaccines.
First, we demonstrated the genetic stabilities of these vaccine strains and also the
complementing cell line. Subsequently, the optimal storage conditions of vaccines,
including additives, temperature, and desiccation, were determined and their protec-
tive efﬁcacies in animals conﬁrmed. Furthermore, to test if mixtures of different vac-
cine strains could be tolerated, we tested cocktails of DISC vaccines in combinations
of three or six different serotypes in sheep and cattle, the two natural hosts of BTV.
Groups of sheep vaccinated with a cocktail of six different vaccines were completely
protected from challenge with individual virulent serotypes, both in early challenge
and after 5 months of challenge without any clinical disease. There was no interfer-
ence in protection between the different vaccines. Protection was also achieved in
cattle with a mixture of three vaccine strains, albeit at a lesser level than in sheep.
Our data support and validate the suitability of these virus strains as the next-
generation vaccines for BTV.
IMPORTANCE Bluetongue (BT) is a debilitating and in many cases lethal disease
that affects ruminants of economic importance. Classical vaccines that afford
protection against bluetongue virus, the etiological agent, are not free from sec-
ondary and undesirable effects. A surge in new approaches to produce highly at-
tenuated, safer vaccines was evident after the development of the BTV reverse-
genetics system that allows the introduction of targeted mutations in the virus
genome. We targeted an essential gene to develop disabled virus strains as vac-
cine candidates. The results presented in this report further substantiate our pre-
vious evidence and support the suitability of these virus strains as the next-
generation BTV vaccines.
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Since the development of the ﬁrst bluetongue virus (BTV) reverse-genetics (RG)system in 2008 (1), there has been a surge of new candidate vaccines against
BTV and related orbiviruses (2–6). The RG system has facilitated the creation of
targeted mutant virus strains that elicit protective antibody responses but avoid the
undesirable side effects of classical attenuated vaccines that had been generated by
serial passages of the virus in tissue culture (reviewed by Dungu et al. [7]). The
mutations associated with attenuation in these classical vaccines are unknown, and
the degree of attenuation and transmission risk of any one vaccine strain is difﬁcult
to assess before its use in the ﬁeld. The new targeted attenuated or replication-
defective orbivirus vaccine strains are highly desirable, particularly for vaccines
against BTV, the causative agent of vector-borne bluetongue disease in ruminant
livestock. There are numerous BTV serotypes (up to 27 serotypes currently identi-
ﬁed) that are endemic around the world, and classical live attenuated vaccines are
marketed for many of these serotypes. Although these vaccines are generally
protective, many vaccine strains do not afford complete protection and often have
severe clinical and teratogenic effects in the fetus themselves (8, 9). Furthermore,
there is very limited cross-reaction between BTV serotypes, and vaccination or
infection with one serotype does not confer protection against other serotypes (10).
More importantly, vaccination with these live virus vaccine strains can result in
viremia sufﬁcient for uptake and onward spread by Culicoides sp. vectors (11)
leading to outbreaks (12) with devastating consequence for the farming industry.
Potentially, this could lead to reversion to virulence and virulent reassortants (13).
Furthermore, live virus vaccines are not distinguishable from the circulating viruses
by serological methods alone (14). Differentiation between infected and vaccinated
animals (DIVA) is important to control the spread of the disease.
The BTV particle is a nonenveloped double-capsid structure consisting of seven
structural proteins (VP1 to VP7) and a genome of 10 double-stranded RNA (dsRNA)
segments (15, 16). The inner capsid or core is made up of two major proteins, VP7 and
VP3, and surrounds three enzymatic minor proteins, VP1 (polymerase), VP4 (capping
enzyme), and VP6 (helicase and RNA packaging protein), in addition to the genomic
dsRNAs (17, 18). The outer capsid is made up of two major proteins: the serotype-
speciﬁc cellular attachment protein VP2 and the membrane penetration protein VP5
(19, 20). Core proteins are highly conserved across the different serotypes; however, the
two outer capsid proteins are variable, particularly the receptor-binding protein VP2.
Four nonstructural proteins (NS1 to NS4) are synthesized in virus-infected cells but are
not part of the virion.
We have exploited the conserved nature of the core proteins, particularly the
enzymatic VP6 protein, to generate a range of serotype-speciﬁc replication-deﬁcient
BTV (viz., disabled infectious single-cycle [DISC] virus vaccine strains) using RG systems.
In previous reports, we have demonstrated the protective efﬁcacy of a number of BTV
DISC vaccines both in sheep and in cattle (2, 3). In current studies, we further
characterize these vaccine strains and generate relevant information required for
successful vaccine production. First, we improved the genetic stability of the DISC virus
strains and determined the optimum storage conditions for the viability of DISC viruses
at room temperature. Desiccation of the DISC vaccine strain in the presence of suitable
additives preserved complete protective immunity of the vaccine in sheep. Further-
more, we demonstrated that protection afforded by DISC vaccine in a single or cocktail
format was effective even as early as 21 days postvaccination (dpv) or as late as over
5 months in vaccinated sheep. Cocktail vaccines were shown to elicit protective
immunity in cattle, albeit at a lesser level than that in sheep at the same dosage. More
importantly, there was no evidence of interference in vaccinated sheep between the
serotypes included in the cocktail vaccine. Overall these data highlight the RG as a very
strong platform to tailor an efﬁcacious and rapid response to outbreaks involving one
or more BTV serotypes.
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RESULTS
Genetic stability of BTV replication-deﬁcient virus and the complementing cell
line. To ensure the genetic stability of replication-deﬁcient viruses (DISC strains), several
stop codons were introduced in the segment S9 that disrupt the expression of VP6
without affecting the length or packaging signals of the S9. The rationale was to
minimize the impact of the changes on the segment’s stability and to reduce any
pressure for reversion after several passages (more than 5 passages in complementing
cells). BTV1 DISC virus was recovered in complementing cells, and its genome proﬁle
was analyzed. Gel electrophoresis of the puriﬁed genomic dsRNAs of passage 5 and 10
viruses had identical proﬁles that are comparable to that of the wild type (WT) (Fig. 1A).
Furthermore, the analysis of sequences of the segment S9 (VP6) found no difference
between the passage 5 and 10 viruses, and there were no unexpected changes in the
sequence of the mutant S9 segment (Fig. 1B). These data suggested that these DISC
viruses are stable after multiple passages.
To ensure further that no reversion occurred during the generation of virus stocks,
viruses grown in complementing BS6 cells at passage 5 or 10 were passaged 3
additional times on noncomplementing BSR cells and in insect Culicoides cells (KC cells).
Infection in cells was monitored for cytopathic effect, the presence of genomic RNA by
reverse transcription (RT)-PCR, and infectious virus progeny by plaque assay. No
replication was detected in any case (data not shown), supporting that the DISC strain
is genetically stable and there is very little possibility, if any, for reversion to infectious
virus.
The stability of VP6 expression in the BS9 complementing cell line was also tested.
In previous reports, the BSR VP6 cell line was used at very low passage number, and the
stability and the level of expression of VP6 after higher passages have not been
assessed (2). Even after 23 passages, the BS9 cells were still expressing VP6 at similar
levels compared to earlier passages (Fig. 1C), indicating that the level of expression was
not affected by serial passages. Furthermore, this cell line was maintained in selective
medium containing puromycin, the selection reagent, but for vaccination purposes,
antibiotics should be removed from the preparation. Therefore, we investigated if the
cell line can be kept without puromycin with minimum effect on VP6 protein expres-
sion. The expression dependency of VP6 on the continuous presence of the puromycin
was not evident in this study as after several passages in medium without puromycin,
FIG 1 Stability analysis of the vaccine virus strain and complementing cell line. (A) Genomic RNA proﬁle
of the BTV1 DISC strain in complementing BS9 cells at passages 5 (P5) and 10 (P10). WT, BTV1 control.
Positions of RNA segments (S1 to S10) are indicated. (B) Sequence electropherograms of S9 RT-PCR
products from passages 5 and 10. Mutations in S9 are underlined, and the sequence of the WT virus is
shown. (C) Expression of VP6 in the complementing BS9 cell line in the presence ( Puro) or absence (
Puro) of puromycin at passages 17, 20, and 23 by Western blotting. Lane C, normal BSR cells; lane M,
protein marker.
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the level of VP6 remained stable (Fig. 1B). These results suggest that viable vaccine
candidates can be prepared in a BTV VP6 cell line in the absence of antibiotics.
Effects of different sugars and temperature on BTV1 DISC virus stability. To
investigate the effect of storage conditions and the incorporation of additives on
maintaining vaccine virus titer, a virus stock was divided into 5 groups, and different
protective agents, such as peptone, lactose, or 5% or 10% trehalose were added.
Furthermore, since storage temperature is also critical, the ability of the different
formulations to maintain particle infectivity was tested at a range of temperatures, from
20°C and4°C to room temperature (24°C). Stocks were stored for either 4 or 28 days
prior to assessing the virus titer. Furthermore, since a low pH in the environment causes
the virus to shed the outer capsid layers, pH was also monitored to ensure that
treatment and storage conditions were not unduly inﬂuencing virus stability. Storage of
the vaccine preparation at 4°C with any of the 3 additives was identiﬁed as the best
condition, with only an 1-log10 drop in titer from day 4 to day 28 (Fig. 2). Storage of
the virus samples at 20°C resulted in a signiﬁcant drop in virus titer (about 5 log10) in
the presence of peptone and lactose but less so in the presence of trehalose. Although
there was a decrease in virus titer (about 1 log10) after the addition of trehalose at all
temperatures, there was no signiﬁcant difference between the day 4 and day 28
samples, with titer remaining consistent at all temperature tested. For all conditions,
the pH ranged from 7.5 to 8.5 with no signiﬁcant variations. These results suggested
that the addition of trehalose to the vaccine strain maintained the infectivity up to 28
days at all temperatures tested.
Elimination of the cold chain is an important improvement in delivering a vaccine to
animals in the ﬁeld and minimizing the cost associated with production and storage.
FIG 2 Optimization of storage conditions for the BTV1 DISC virus. (A) Virus titers in the presence of
peptone, lactose, or trehalose at the indicated temperature (4°C, 20°C, or 24°C) at 4 and 28 days. Titers
were expressed as PFU per milliliter and plotted in logarithmic scale. (B) Virus titers after desiccation in
the presence of peptone, lactose, or two concentrations of trehalose (5% and 10%). No additive (PBS) and
4°C storage were included for comparison.
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The effect of addition of different stabilizing reagents (peptone, lactose, or trehalose)
followed by desiccation on DISC vaccine titer was analyzed and compared to that of a
nondesiccated preparation kept at 4°C (Fig. 2). The addition of these additives did not
affect the virus infectivity, with titers similar to those of the control (media only) stock
virus (1 107 to 5 107 50% tissue culture infective doses [TCID50]/ml). This result was
consistent with initial screening results (Fig. 2). The storage at 4°C with peptone alone
resulted in a titer decrease from 1  107 to 5  107 TCID50/ml to 1  106 TCID50/ml.
The effect of desiccation was also assessed and resulted in a decrease of 0.6 to 4 log10
in virus titer in all samples. The addition of 10% trehalose to the media maintained the
infectivity of the virus in comparison to those of peptone, lactose, and 5% trehalose.
The virus titers decreased from a range of 1  107 to 5  107 TCID50/ml to a range of
1  104 to 1  105 TCID50/ml. The addition of 10% trehalose to virus stocks prior to
desiccation provided the best means to maintain infectivity. Desiccated stocks kept at
room temperature or 4°C for up to 8 weeks also appeared to maintain virus titer.
Inﬂuence of vaccine desiccation on immunological response and protection to
BTV1 challenge. The effect of trehalose and desiccation on neutralizing antibody
responses in sheep was also examined. A group of 6 sheep was vaccinated with the
desiccated DISC virus using the standard two-dose regimen of 21 days apart (at days 0
and 21). A control group of 6 animals was vaccinated with only phosphate-buffered
saline (PBS) as described previously (21). Development of the BTV antibody response in
sheep was monitored by a VP7 group-speciﬁc antigen enzyme-linked immunosorbent
assay (ELISA). As expected, sheep in the control group did not trigger any antibody
response to VP7. However, all vaccinated animals were seroconverted. Sera of all
vaccinated animals had antibodies that recognized VP7 by day 7 after the ﬁrst vacci-
nation and remained positive until the end of the experiment. The data indicated that
the desiccation or trehalose did not alter the conformation of VP7 of the DISC virus and
possibly the overall biological property of the DISC virus strain remained intact (Fig. 3A).
To further investigate if the VP2 structure was not disrupted by desiccation and that the
vaccinated sheep still elicited neutralizing antibodies against virulent BTV1 virus, each
sheep serum was assessed for virus neutralization in tissue culture. All animals inocu-
lated with the desiccated vaccine in a prime-boost regimen had detectable neutralizing
antibodies (seroneutralization titers of 8 to 128) after the second inoculation (Fig. 3B).
Both control and vaccinated animal groups were challenged with virulent BTV1 on
day 42. The vaccinated sheep did not develop fever or display any clinical symptoms of
BT. However, all control sheep had fever for 5 days after challenge, with a peak at 7 days
postchallenge (dpc) (Fig. 3C). These animals also showed classical clinical signs of BT
(Fig. 3D), including increased rate of breathing, mild depression, decrease in appetite,
and conjunctivitis after challenge with virulent BTV1.
Serological analysis demonstrated that all postchallenged sheep elicited a response
to the BTV group-speciﬁc antigen VP7, by ELISA (Fig. 3A). Furthermore, neutralizing
antibodies against BTV1 were detected in all animals (Fig. 3B). Prior to challenge,
vaccinated animals had detectable SN titers, which were still maintained until the end
of the experiment. However, in the control group, neutralization titers were detectable
only after the challenge.
To ensure that the vaccine was not only protecting against disease but was
completely efﬁcacious in preventing virus replication, blood samples of each animal
were examined for circulating viral genome by reverse-transcription quantitative PCR
(RT-qPCR). None of the animals inoculated with the DISC vaccine had any detectable
circulating BTV1 (Fig. 3E). In comparison, BTV1 genome was detected in all of the
control animals. A typical viremic response was observed for the control group: peak
viremia occurred at day 6 followed by a slow reduction of the virus in the circulating
blood (Fig. 3E).
Early protection afforded by a MultiDISC (BTV1, -2, -4, -8, -13, and -21) vaccine
trial in sheep. Our previous study demonstrated that a vaccine cocktail of six DISC
serotypes (BTV1, -2, -4, -8, -13, and -21) induced neutralizing antibodies and afforded
protection against a virulent BTV challenge (3). To investigate if this protection can be
Next-Generation Vaccines for BTV Journal of Virology
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afforded early after vaccination, two groups of six sheep were vaccinated with the
multivalent vaccine (MultiDISC) and challenged 21 days after the vaccination with
either BTV2 or BTV8 serotypes.
The immune response to the vaccine was evident as all animals were seroconverted
as early as 7 dpv, as shown in the competitive ELISA (cELISA) (Fig. 4A). While progressive
decrease in the titer of VP7 antibodies was observed until the day of the challenge (day
21) with the early-detection ELISA, the titers remained stable with the cELISA. At the
challenge day, animals were still positive. However, the seroneutralization (SN) re-
sponse of vaccinated animals was much weaker. BTV neutralization was undetectable
in almost all vaccinated animals, except in only one sheep, which had a titer of 16 to
32 for BTV1 and BTV4 (data not shown).
FIG 3 Immune response and protection afforded by BTV1 DISC vaccine in sheep. The immune response
to the vaccine was monitored by VP7 group-speciﬁc competitive ELISA (A) and seroneutralization test (B)
at different time points. Animals were inoculated twice (empty arrows) with BTV1 DISC vaccine at days
0 and 21 (group 1). The control group was inoculated with cell lysate. All animals were challenged at day
42 (full arrow). (C) Body temperature (oC) and (D) clinical scores were recorded daily for the vaccinated
(group 1) or nonvaccinated (control) animals. (E) Detection of BTV genome in blood after challenge by
qRT-PCR. A CT value lower than 40 was considered positive for BTV replication.
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All animals in the vaccinated groups showed protection from BTV infection, albeit at
different levels by a diagnostic pan-BTV real-time RT-PCR in blood samples (Fig. 4B). The
genomic copy number detected indicates that in the BTV8-challenged group, 3 out of
4 animals remained negative, with the exception of borderline RNA detections after
challenge (1 to 4 dpc), probably due to the detection of the inoculated challenge virus.
The 4th animal became positive at 3dpc, with a maximum at 4 dpc, and copy numbers
never exceeded 2  103 copies/reaction (c/r). Subsequent samples remained positive
until 19 dpc, although with decreasing copy number. In comparison, the mean maxi-
mum copy number in the control animals infected with BTV8 was 1.26  107 c/r. These
results indicate that although the immunity is not 100% sterile in all of the vaccinated
and subsequently challenged animals, the viremia seen in the one animal was signif-
icantly lower (almost 4 log units) than that of the control animals (Fig. 4B).
In the BTV2-vaccinated group, all animals became PCR positive after challenge. The
copy number increased to a maximummean of 5 105 c/r. Nevertheless, this value was
signiﬁcantly lower than the mean maximum of 1.25  107 c/r in the BTV2-infected
control animals, demonstrating the important effect of the vaccine. Altogether, the data
indicate that the replication-deﬁcient virus has a protective effect on vaccinated
animals even a few days after inoculation.
Duration of immunity of MultiDISC vaccine in sheep. Understanding the long-
lasting protection afforded using this vaccine is essential to control an outbreak and
FIG 4 Early protection in sheep vaccinated with a MultiDISC vaccine. (A) Seroconversion of vaccinated
and control animals by group-speciﬁc VP7 competition ELISA. All animals were vaccinated once (open
arrow) and challenged at 21 dpv (solid arrow). (B) Virus load in blood was tested by qRT-PCR and
calculated as the average number of copies per reaction per group.
Next-Generation Vaccines for BTV Journal of Virology
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prevent spreading of the disease. For BTV immunity, we analyzed the duration of the
protection afforded with the MultiDISC vaccine, including the same serotypes tested
previously. The immunization scheme included two doses, 21 days apart, and a
challenge with a virulent strain (either BTV2 or BTV8) after 154 days.
All vaccinated animals seroconverted at 7 dpv, and a clear booster effect was seen
in all animals after a second dose with high titers until challenge at 154 dpv (Fig. 5A).
Following challenge, the immune response titer remained high and stable until the end
of the experiment. All control animals were negative at the start of the test, but clinical
signs were evident 5 dpc with a virulent strain (data not shown) and seroconverted at
7 dpc (Fig. 5A).
Presence of BTV RNA was monitored by pan-BTV diagnostic real-time RT-PCR in
blood samples and expressed as average cycle threshold (CT) per group (Fig. 5B).
Following challenge with either BTV2 or BTV8 strains at 154 dpv, no indication of virus
replication was observed for the vaccinated/challenged animals, and this remained so
until the end of the experiment, suggesting complete protection. Between 1 and 3 dpc,
all control animals became viremic with very high genomic copy numbers suggesting
BTV replication in these unprotected animals. Although the genome derived from the
FIG 5 Long protection test in sheep vaccinated with a MultiDISC vaccine. (A) Detection of group-speciﬁc
antibody response (against BTV VP7) using competition ELISA. Animals were vaccinated twice 21 days
apart (empty arrows) and challenged 154 dpv (full arrow). (B) Virus load was determined by RT-PCR, and
the results were expressed as mean CT values. The dashed line represents the PCR cutoff; results below
the line are considered negative.
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DISC strain was detected after each vaccination, all animals were negative on the
challenge day, supporting that the vaccine was not able to replicate in the host.
The nature of the immune response in this long-duration experiment was further
analyzed by determining the neutralization activity in the sera of vaccinated animals.
Two time points—21 days after the boost (42 dpv) and at 154 dpv, the day of the
challenge—were tested for neutralization activity against all serotypes included in the
vaccine cocktail. At 42 pdv, all animals presented some level of neutralization against
at least one serotype in the vaccine (Fig. 6A). Two animals responded poorly, and one
of them showed reactivity only against BTV1. As expected, the long-term neutralization
activity was lower at 154 dpv (Fig. 6B). Seven animals showed some neutralization
activity against at least one serotype, and only one animal showed no signiﬁcant
neutralization.
Evaluation of TriDISC vaccination (BTV2, -4, and -8) in cattle. In a previous report, we
showed that cattle vaccinated with monoserotype DISC virus BTV2, BTV4, or BTV8 were
able to elicit a protective neutralizing antibody response (3). To investigate the effec-
tiveness of a cocktail vaccine containing three BTV serotypes (BTV2, -4 and -8 [TriDISC])
in cattle, two independent trials were undertaken. In the ﬁrst trial, 15 animals were
vaccinated, and 9 were used as controls. In the second trial, 12 animals were vaccinated,
while 6 were used as controls. In both trials, animals were inoculated twice with the
TriDISC cocktail and challenged with BTV2, BTV4, or BTV8 virulent strains.
A pronounced immune response was detected in all cattle vaccinated with the
TriDISC cocktail after boost vaccination by group-speciﬁc cELISA in both trials (Fig. 7A
FIG 6 Long-term neutralization activity in sheep inoculated with a MultiDISC vaccine. Neutralizing titer
was tested against all serotypes included in the cocktail vaccine at two time points: 42 (A) and 154 (B)
days postvaccination. Titers below the threshold (dashed line) were considered negative.
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and B) and remained positive until challenge, indicating all animals were serocon-
verted.
The immune response was further analyzed by determining the neutralization titer
by seroneutralization (SN) assay for the animals on the challenge day. The SN titer in the
ﬁrst trial showed a weak response (8), with only one animal with a detectable titer
(16) against BTV4. Because a weak neutralization titer was detected in the ﬁrst trial,
in the second trial, a higher dose of DISC virus was used to improve the immune
FIG 7 Immune response in cattle inoculated with a TriDISC cocktail vaccine. Two trials were performed
(A and B). Animals were vaccinated twice 21 days apart (open arrows) and challenged at 42 dpv (solid
arrow). Seroconversion was monitored by a BTV serogroup-speciﬁc ELISA. For each group, the mean and
95% conﬁdence interval are shown.
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response. In the second trial, the response was more promising. On the challenge
day, 67% of the vaccinated animals (8 out of 12) had neutralizing titers between 16
to 64 against BTV8. No SN titer was detected for BTV2 and BTV4 included in the
vaccine. None of the control animals showed any neutralizing antibody response on
the challenge day.
After challenge with virulent virus, viral genome was detected by RT-qPCR in the
blood of all animals in the three control groups on 3 or 4 dpc with high copy numbers
(Fig. 8). In the BTV2 challenge group of the ﬁrst trials, 3 out of 5 vaccinated animals were
positive for more than 1 day, compared to the second trial group, where 75% of animals
were protected as only 1 out of 4 was positive. Similar results were obtained with
BTV4-challenged groups, with 4 out of 5 positive in the ﬁrst trial group and 2 out of 4
in the second trial group, consistent with the weak neutralizing antibody response or
lack of response in these animals.
FIG 8 Viral load in cattle inoculated with a TriDISC cocktail vaccine after challenge with virulent BTV. BTV
genomic RNA content in serum was measured by real-time RT-PCR. Animals were vaccinated with the
cocktail vaccine and challenged with BTV2 or BTV4 or BTV8 as indicated. Low to high loads (high to low
CT values) are represented by a color gradient from green to red.
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In contrast, animals challenged with BTV8 were better protected, as 3 out of 5 (ﬁrst
trial) and 3 out of 4 (second trial) showed no virus replication.
In addition to the prevention of viremia, in 14 of 27 (combined ﬁrst and second
trials) animals (52%), a clear effect of the vaccination was also seen in viremic animals
in the vaccination groups. Their viral loads were signiﬁcantly reduced compared to
those in the controls. In the BTV2 challenge group, the mean CT value among PCR-
positive samples from vaccinated animals was 32.3  2.6, compared to 28.8  3.05 in
the control animals, for BTV4, it was 31.7  4.1 versus 27.8  3.2, and for BTV8, it was
33.3  4.5 versus 28.9  3.7 (Fig. 8). No obvious clinical signs attributable to BTV
infection were observed in the TriDISC-vaccinated cattle. In control animals, on the
other hand, clinical signs included nasal and ocular discharge and respiratory distress,
as well as muco-cutaneous lesions around the nose and mouth, with overall clinical
scores between mild and moderate.
DISCUSSION
In recent years, a number of new types of vaccine candidates for BTV have been
developed using reverse genetics of BTV. Although several of these candidate vaccines
have been shown to elicit protective immunity in sheep, none have been commercial-
ized to date. In this report, we investigated a number of essential vaccine parameters
of our replication-deﬁcient DISC virus strains to forward these candidate vaccines to the
marketplace. One of the most important criteria is the genetic stability of these vaccine
strains, which were initially designed to exclude an essential gene of the viral genome
replication by deleting the VP6 coding region of segment S9 altogether (2). Since large
deletions often compromise genetic stability, we generated an alternate VP6-deﬁcient
virus in which multiple stop codons were introduced into the gene. We found that this
strategy has all the beneﬁts of the VP6 deletion mutant viruses that we reported
previously but superior genetic stability compared to the previously reported construct
(2). There was no evidence of genetic pressure for reversion after multiple serial
passages. Furthermore, for the ﬁrst time, the optimization of the storage conditions of
this vaccine strain was undertaken in the presence of stabilizing reagents followed by
desiccation at room temperature. These conditions were shown to have minimal
impact on vaccine virus titer. Moreover, these desiccated DISC vaccines were able to
induce immune responses in a typical double-dose protocol 21 days apart that con-
ferred complete protection in vaccinated sheep against virulent virus challenge, sug-
gesting vaccine efﬁcacy was not compromised by desiccation at room temperature.
Additionally, and in compliance with the manufacturing requirements of vaccine
formulations without antibiotics, we demonstrated that the complementing VP6 cell
line maintains a constant level of VP6 expression even at high passage numbers and in
the absence of the selective agent (puromycin) in the growth media. Altogether, our
data showed that the DISC vaccine strain is genetically stable, and its virus titer can be
maintained by desiccation in the presence of stabilizing reagents. These features are
essential for mass production and vaccine administration in the ﬁeld as no cold chain
for delivery and handling is needed.
During an outbreak of BT disease, it is essential that the vaccination strategy
respond fast and efﬁciently to the threat affording protection as early as possible to
minimize the risk of infection and spread. In a previous report, we demonstrated that
a single dose of a DISC virus strain was sufﬁcient to confer complete protection against
a challenge in sheep 42 days after vaccination (2). In the present study, we further
demonstrated that a single dose of the 6 different serotypes in a cocktail could also
protect animals as early as 21 days after vaccination as no viremia was detected in
vaccinated and challenged sheep. Furthermore, previously we reported that a cocktail
of six different DISC virus strains representing six BTV serotypes was completely
protective in sheep against the virulent strains that were tested, indicating the possi-
bility of generating a mixture of vaccine strains without any interference between
different serotypes (3). However, the vaccinated animals were challenged at 42 days
after vaccination. Here, we used the same combination of cocktail and demonstrated
Celma et al. Journal of Virology
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the long-term protective efﬁcacy of this cocktail by challenging the animals after 154
days of vaccination. Overall these results suggest that even when the neutralization
activity in sera was very low in vitro, the immune response of the sheep afforded by this
MultiDISC vaccine was sufﬁcient to confer protection against representative virulent
strains included in the cocktail even more than 3 months after vaccination.
Virus-like particles (VLPs) of BTV had also been shown to afford long-term (up to 14
months) protection in sheep (22). A similarly inactivated vaccine (23) and a live
attenuated (24) vaccine have also been shown to elicit immune responses 1 year after
vaccination. Therefore, it is likely that DISC vaccines could also sustain their immune
responses in animals for a long duration. However, further studies will be needed.
Supporting the potential of these next-generation vaccines as candidates for BTV
control, in recent years, RG-based strains bearing mutations that abolish the expression
of one of the nonstructural proteins (NS3/NS3A) have been developed (5). These
disabled infectious single-animal (DISA) vaccines are different from our strains because
they are highly attenuated live virus strains, as these viruses are capable of replication,
although at a very low level. Current live attenuated BTV vaccines that are used in the
ﬁeld are not completely safe as some are linked with undesirable secondary reactions,
such as teratogenic effects, reversion to virulence, and the risks of transmission to
vectors. Vaccine studies with these DISA vaccines showed protection in vaccinated
animals and inability to replicate in the Culicoides vector (25). The vaccine candidates
that we are presenting in this report do not replicate either in cell culture or in the
susceptible hosts and in that respect are more similar to an inactivated vaccine, but
with several advantages. No inactivation process that increases the production cost is
necessary with the DISC vaccines, making these vaccines more cost-effective. More
importantly, since DISC strains cannot complete a replication cycle in normal cells or in
the bloodstream of a vaccinated host, DISC strains are present only for a short period,
thus minimizing the risk of transmission to insect vector, reassortment, or reversion to
virulence. However, these defective strains are capable of entering the cells and
expressing viral proteins (2) that are available for the host immune system for an
improved response.
Results for the efﬁcacy of the candidate vaccines were slightly different between the
two hosts, cattle and sheep. The results of the competitive ELISA revealed a weak
humoral immune response after the ﬁrst dose of the TriDISC vaccination in cattle.
The good antibody response after the second dose suggests that double doses of
DISC cocktail vaccines are necessary for cattle, at least with the dosages tested, different
from the outcome of the sheep vaccination trials. Nevertheless, a majority of cattle
vaccinated with the TriDISC cocktail vaccine in the second trial were completely
protected against virulent challenge. Since the SN titer was very low in cattle, no clear
correlation between the neutralizing response and the viremia could be established,
and further studies are needed to determine other factors involved in the protection
(i.e., T cell response). Although the ﬁrst trial group had a lower titer of DISC vaccines
than the second group and some animals had low levels of BTV replication, overall, the
TriDISC vaccination induced a signiﬁcant reduction of the BTV viral load in peripheral
blood and protected against clinical disease in all animals. Furthermore, it is known that
a reduction of viremia also markedly reduces the risk of transmission by Culicoides
midges (11). Therefore, the TriDISC vaccine would most likely have a strong impact not
only on the clinical outcome but also on the virus spread.
It is noteworthy that sheep could be protected by inactivated (26) or DISC (2)
vaccines with a single-shot application, while cattle generally needed two applications
for complete protection (27). In addition, the observed pattern of neutralizing activity
could indicate interference between the serotypes included as reported for live atten-
uated vaccine strains (28, 29). This possible interaction should be further studied, and
the role of the strains’ differences and virus titers should be investigated. Different
strain combinations or higher titers for particular strains in cocktail vaccines need to be
tested in order to improve protection. Additionally, commercial and some experimental
vaccines include in their formulation adjuvants such as aluminum hydroxide, Mon-
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tanide ISA 206 (Seppic), or immunostimulating complex (ISCOM) that increase the
immune response (30–32). Adjuvants were not included in this trial but can be
beneﬁcial in the formulation of the replication-deﬁcient cocktail vaccines for cattle, a
possibility that needs to be explored.
It is noteworthy that in the early-detection and long-duration trials in sheep
presented in this report, the genome of the vaccine strain was detected in the blood
for only a short period and at a very low levels after each inoculation. Since genomes
of the vaccine strains are deﬁcient of replication, there is no possibility for reassortment
between the vaccine strains and infecting virus strains.
Replication-deﬁcient vaccine strains are promising candidates for commercial de-
velopment to control BTV. Research into the mechanisms involved in the response to
these vaccines will help to develop a platform for a rapid response to a potential
outbreak with single or multiple serotypes.
MATERIALS AND METHODS
Cell lines and viruses. BSR cells (a BHK-21 subclone) were maintained in Dulbecco modiﬁed Eagle
medium (DMEM [Sigma-Aldrich]) supplemented with 5% (vol/vol) fetal bovine serum (FBS [Invitrogen]).
The stable BSR-VP6 cell line BS9 was grown in DMEM supplemented with 5% FBS and 7.5 g/ml of
puromycin (Sigma-Aldrich) as previously described (2, 21). Parental BTV and DISC virus stocks were
obtained by infecting BSR or BS9 cells, respectively (2, 3). Titration of all deﬁcient viruses was performed
in the BS9 cell line, and the virus titer was determined by plaque assay (PFU) or endpoint titration (50%
tissue culture infective dose [TCID50]) as described previously (33).
Recovery of replication-deﬁcient BTV1 DISC virus. A triple-stop-codon mutation at residues 87 to
89 in VP6 was introduced into BTV10 S9 by site-directed mutagenesis (34) using the T7 plasmid
pUCT710S9 (2) and the following primers: 10S9TS257-F (5=-GACGCATACATACTGCATAATAATGAGGATCA
GGCACAAAAGG-3=) and 10S9TS257-R (5=-CCTTTTGTGCCTGATCCTCATTATTATGCAGTATGTATGCGTC-3=).
For virus recovery, the BTV reverse-genetics system was used (2).
Stability of the vaccine strain BTV1 DISC and the stable cell line BS9. The genetic stability of the
replication-deﬁcient virus was tested by serial passage of the virus in the complementing cell line BS9.
After 5 and 10 passages, the genomic dsRNA was extracted and puriﬁed using Tri reagent (Sigma-Aldrich)
and analyzed by 11% PAGE in the presence of ethidium bromide.
The level of VP6 expression in the complementing BS9 cell line was assessed after serial passages in
media in the presence or absence of puromycin. Cell lysates were analyzed at passage numbers 17, 20,
and 23, and the expression of VP6 was detected by Western blotting using a speciﬁc antibody against
BTV VP6. As loading control, the cellular protein -actin was detected using a monoclonal anti--actin
antibody (Sigma-Aldrich).
Virus stability at different storage conditions was tested by the addition of protective agents to the
deﬁcient virus stock BTV1 DISC. Three different additives were used for the stability test: peptone (1%
Bacto peptone in phosphate-buffered saline [PBS]), lactose (1% lactose, 1% Bacto peptone in PBS), or
trehalose to a ﬁnal concentration of 5% or 10% prepared in PBS. Each additive was added to 1-ml aliquots
of the vaccine sample and stored at 20°C, 4°C, or room temperature (24°C). Duplicate samples were
taken at 4 and 28 days, and their infectivity was determined by titration.
For the desiccation test, additives were added to each sample and subjected to desiccation using a
SpeedVac concentrator (Savant) until completely dry. The following day, the vaccines were reconstituted
and the titer monitored. As a control, nondesiccated aliquots were stored at 4°C.
Monoserotype vaccination with BTV1 DISC in sheep. To assess the efﬁcacy of the BTV1 DISC
vaccine candidate after addition of trehalose (10%) and desiccation, 10-month-old healthy male and
female sheep (Crossbred Pre Alps) were used. The animals were free of respiratory, digestive, umbilical,
parasitic, and osteo-articular diseases and were seronegative for BTV by competitive ELISA test. Two
groups of 4 to 6 animals were segregated at random. Group 1 was vaccinated twice with the vaccine (1
107 TCID50) by the subcutaneous route on the lateral side of the thorax, 21 days apart. Group 2 was
inoculated with a BTV-free BS9 cell lysate and was used as control. On day 42, all animals were challenged
with BTV1 (4110. 13.06 BTV1 KC2), which was isolated from blood of an infected bovine in 2013 in Corsica
(35), followed by passaging in KC cells twice. Several intradermal injections on the inner side of the right
thigh were given. Clinical data were recorded as described previously (36). At the end of the experiment,
all animals were sacriﬁced. Animals were treated according to the ethical rules of national and European
regulations on animal welfare. Whole blood and sera were collected routinely (as indicated) to monitor
the antibody response to BTV antigens and virus load.
MultiDISC (BTV1, -2, -4, -8, -13, -21) vaccination trials in sheep. All sheep experiments were performed
under the guidelines of the European Community and were approved by the Committee on the Ethics of
Animal Experiments of the Central Veterinary Institute (permits 2013.015 and 2013.016). Female Blessumer
sheep (6 to 24 months old) were obtained from a Dutch farm and were free of BTV and BTV antibodies. Sheep
were allocated randomly to groups of four animals at 1 week before the start of the experiment.
Early protection. Sheep of two groups were vaccinated with 1 ml MultiDISC vaccine (between 5 
106 and 4  107 PFU/serotype). Two groups were mock vaccinated with BTV-free cell lysate. Sheep were
injected subcutaneously (s.c.) over the back between the shoulder blades on both sides of the spinal
cord. At 21 dpv, one vaccinated group and one nonvaccinated group were s.c. injected in 4 different
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places with 105 TCID50 of BTV8/net07 (isolated on eggs and passaged three times on BHK-21 cells
[BTV8/net07/e1/bhkp3]) or BTV-2/SAD2001/01 (isolated from sheep at the Pirbright Institute, United
Kingdom, and grown once in embryonated chicken eggs, with two passages on BHK-21 cells and three
passages on KC cells [BTV2/SAD01/01/e1/bhkp2/kcp3]) and used in a previous report (3). Samples of
serum and EDTA-treated blood were collected at indicated days of the experiment. Clinical signs were
scored as previously described (36).
Duration of immunity. Sheep of two groups (8 animals per group) were vaccinated with 1 ml of
MultiDISC vaccine as described for early protection. At 21 dpv, animals received a booster vaccination.
At 154 dpv, one group was injected with BTV8/net07 and the other group with BTV-2/SAD2001/01
virulent virus as described for early protection. EDTA-blood and serum were collected to monitor the
antibody response and virus load.
TriDISC vaccination trial in cattle. Two independent trials were designed to test protection of a
cocktail vaccine in cattle. For the ﬁrst trial, 15 heifers were subcutaneously inoculated with a mixture of
the BTV2, -4, and -8 DISC viruses at 3.6  107 PFU/animal (3.8  106 to 2  107 PFU/individual serotype).
In addition, 9 animals were mock vaccinated with BTV-free cell lysates. In the second trial, a total of 12
cattle were inoculated with the same mixture of BTV2, -4, and -8 DISC viruses but at a higher dose: 7.5 
107 PFU/animal (8  106 to 3  107 PFU/individual serotype). An identical booster injection was given
21 days after the ﬁrst vaccination. Three weeks after the second vaccination (42 days after the ﬁrst), the
vaccinated animals were segregated into three groups and challenged subcutaneously with 105 TCID50s
of a virulent isolate of either BTV2 (BTV-2/SAD2001/01 E1/BHK2/KC1), BTV4 (BTV-4/MOR2009/07 KC1), or
BTV8 (BTV-8/DE08/BH97/Vero2/BKK1). In parallel, 6 animals were mock vaccinated with BTV-free cell
lysates. Whole-blood and serum samples of all animals were taken at regular intervals before and after
vaccination and challenge. Clinical data were recorded as described previously (36).
RNA extraction and RT-qPCR. RNA extraction from the EDTA-blood samples was performed
according to Vandenbussche et al. (37). The triplex RT-qPCR assay included primers and probes for a
pan-BTV/S5-speciﬁc reaction and for an internal control (IC) and external control (EC) as described by
Vandenbussche et al. (37) and was performed on a LightCycler-480 (Roche Diagnostics). For this assay,
cycle threshold values (CT values) of40.0 were classiﬁed as positive, CT values of40.0 and45.0 were
classiﬁed as doubtful, and CT values of 45.0 were considered negative. External standard curves were
used for absolute quantiﬁcation.
Alternatively, viral RNA was extracted from collected blood samples using a commercial extraction kit
(Macherey-Nagel), and BTV RNA quantiﬁcation was achieved by qRT-PCR using the Adiavet BTV detection
kit (Adiagene) according to the protocols developed by Toussaint et al. (38). The viral RNA copy numbers
of the samples were inferred from a standard curve obtained after speciﬁc ampliﬁcation of a synthetic
BTV RNA (segment S1) run in parallel.
Serology of MultiDISC and TriDISC trials. Serum samples were analyzed with a commercially
available BTV VP7 antibody test kit (competitive ELISA [cELISA]; IDEXX) according to the manufacturer’s
instructions.
The results were expressed as percentage of negativity compared to the negative kit control (P/N)
and transferred to positive (70%), doubtful (70% to 80%) or negative results (80%). Serological
status was deﬁned as positive (30%), doubtful (25% to 30%), or negative (25%).
For detection of neutralizing antibody response in vaccinated animals, a standard seroneutralization
(SN) assay was used as described previously (2). Brieﬂy, serum samples were serially diluted 1:2 and
added to conﬂuent monolayers of BSR cells in 96-well plates. About 100 infectious BTV particles were
added to each well and incubated for 3 days. All dilutions were performed in triplicate for each
experiment. The neutralizing titer was deﬁned as the highest dilution of sera allowing complete
neutralization of the virus.
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